The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ICC/IF: Use at an assay dependent dilution.
RipA: Use at an assay dependent dilution.
WB: 1/5000. Predicted molecular weight: 24 kDa.
Titer in ELISA/WB using rNEF of HIV 1 Subtype A.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Nef is a early protein that appears to play a role in optimizing the host cell environment for viral replication without causing cell death by apoptosis. Nef enhances virus infectivity and pathogenicity. It down modulates surface MHC I molecules and internalized molecules are sequested to the trans-Golgi network. The number of cell surface CD4 antigen are decreased by interacting with the Src family kinase LCK thereby inducing LCK CD4 dissociation and by increasing clathrin-dependent endocytosis of this antigen to target it to lysosomal degradation.
C terminal core protein antibody
F protein antibody
Negative factor antibody
Anti-HIV1 Nef antibody [JR6] 画像
Western blot - Anti-HIV1 Nef antibody [JR6] (ab42358)
Lane 1 : Anti-HIV1 Nef antibody [JR6] (ab42358) Lane 2 :
Lane 1 : Recominant HIV1 Nef (B subtype) Lane 2 : Protein size marker
Kjerrström A et al. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology284:46-61 (2001).
Read more (PubMed: 11352667) »
Collings A et al. Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunised with non-replicating or self-replicating expression vectors. Vaccine18:460-7 (1999).
Read more (PubMed: 10519935) »